Summit Therapeutics (SMMT) Equity Ratio (2019 - 2025)
Summit Therapeutics' Equity Ratio history spans 7 years, with the latest figure at 0.73 for Q3 2025.
- For Q3 2025, Equity Ratio fell 15.65% year-over-year to 0.73; the TTM value through Sep 2025 reached 0.73, down 15.65%, while the annual FY2024 figure was 0.89, 133.15% up from the prior year.
- Equity Ratio reached 0.73 in Q3 2025 per SMMT's latest filing, down from 0.8 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.9 in Q1 2025 to a low of 0.19 in Q4 2022.
- Average Equity Ratio over 5 years is 0.62, with a median of 0.57 recorded in 2024.
- Peak YoY movement for Equity Ratio: plummeted 74.04% in 2022, then soared 258.72% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.73 in 2021, then tumbled by 74.04% to 0.19 in 2022, then surged by 100.75% to 0.38 in 2023, then soared by 133.15% to 0.89 in 2024, then fell by 17.7% to 0.73 in 2025.
- Per Business Quant, the three most recent readings for SMMT's Equity Ratio are 0.73 (Q3 2025), 0.8 (Q2 2025), and 0.9 (Q1 2025).